Response to: SARS-CoV-2 and type I interferon signaling in brain endothelial cells: Blurring the lines between friend or foe.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

1. Emerging Perspectives on Prime Editor Delivery to the Brain.Pharmaceuticals (Basel, Switzerland) · 2024
   Review
2. A Brief Overview of Neutrophils in Neurological Diseases.Biomolecules · 2023
   Review
3. Not myopathic, but autonomic changes in patients with long-COVID syndrome: a case series.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023
   Article
4. COVID-19 and neurodegeneration: The mitochondrial connection.Aging cell · 2022
   Article

Corrections and comments

• Comment on
  The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2.2022
• Comment on
  SARS-CoV-2 and type I interferon signaling in brain endothelial cells: Blurring the lines between friend or foe.2022

Authors and funding

3 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as